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Introduction
Ankylosing spondylitis (AS), which is the most frequently occurring form of spondyloarthritis (SpA), is a chronic immune-mediated inflammatory disease characterized by inflammation that predominantly affects the axial skeleton (1) . Inflammatory bowel diseases (IBD) (Crohn´s disease (CD) and ulcerative colitis (UC)) are most frequent extraarticular manifestations of AS. Although the most significant genetic association for SpA is with the genes related to the MHC (HLA-B27), several polymorphisms outside the MHC were identified, including IL-23R, PSMG1, ERAP1/2 and TNFSF15 which are also established IBD loci (2) . The discovery of several inflammatory pathways in both AS and IBD led to the era of the biologic therapies, which meant a revolution in their treatment and prognosis. All tumor necrosis factor α inhibitors (TNF-α inhibitors) are efficacious in treating AS, but there are differences regarding IBD. Monoclonal antibodies (infliximab (INF), adalimumab (ADA), certolizumab-pegol (CPG), golimumab (GOL)) are efficacious in the treatment of IBD whereas etanercept (ETA) is not (3) . Paradoxal adverse events (PAEs) refer to occurrence of pathological condition opposite to the effect which would normally be expected. The development of IBD during the treatment with TNF-α inhibitors is seen in patients with AS. CD is the mainly developing form of IBD, and ETA is most frequently associated agent. Paradoxal IBD is generally well controlled by the interruption of the damaging TNF-α inhibitor and switching to a monoclonal antibody.
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Essential trombocythemia (ET) is a Philadelphia chromosome (Ph)-negative myeloproliferative neoplasm (MPN) characterized by thrombocytosis and megakaryocytic hyperplasia of the bone marrow, with the presence of Janus kinase 2 valin 617 phenylalanine (JAK2V617F) mutation in 50-60% of patients. ET can transform into myelofibrosis and acute myeloide leukemia in minority of cases and, in general, life expectancy is considered not far from that of healthy population (4). HLA-B27 has been suggested to be important in the pathogenesis of AS, furthermore; HLA-B27 seems to also raise risk for hematological malignancies, notably myelodysplastic syndrome (MDS), acute leukemia and lymphoid malignancies but not Ph-negative MPN (5).
Case report
We report a 35-year-old men presented with a 10-year history of morning pain and stiffness in the low back, buttocks and hips. He was positive for human leukocyte antigen (HLA-B27) and plain radiography showed bilateral sacroilitis. Based on modified New York criteria, patient was diagnosed with AS in 2005 (6) . He started with nonsteroidal antiinflammatory drugs (NSAIDs), but after several months sulfasalazine (SSZ) 2 g/day was introduced due to right knee arthritis. Only after methotrexate (MTX) 17.5 mg/week was administered, patient started to feel better.
Even before he was diagnosed with AS, in 2002, he was examined due to symptoms of erytromelalgia and thrombocytosis. After bone marrow biopsy preliminary diagnosis of ET was made. Patient was advised to take antiplatelet drug and to undergo further evaluation.
However, he decided to visit hematologist four years later, when erytromelalgia symptoms got worsened. Further analysis proved JAK2V61F7 mutation, breakpoint cluster regionAbelson (BCR/ABL) rearrangement was negative and cytogenetic analyses were normal.
Bone marrow aspiration and repeated bone marrow biopsies showed hipercellularity with dominant megakaryocytic hyperplasia (7). After definite diagnosis of ET was made (November 2006), he started taking aspirin, but when anagrelid was introduced his PLT count was below 1000 cells/mm³. At that time, he was taking SSZ and MTX for AS and disease activity was mild (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score 3.7)
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After two years, in July 2008, his laboratory findings indicated hepatotoxicity. Roussel Uclaf Causality Assessment Method (RUCAM) score for drug-induced liver injury was performed for all medications that the patient was taking when the elevated liver enzymes were noted (8) . MTX was assigned the highest RUCAM score at 6 (the probable cause of liver injury), SSA was 3 (possible cause) and anagrelid was 1 (unlikely cause). According to RUCAM scoring results, SSZ and MTX were suspended. Soon, his back pain worsened, BASDAI was 6.7 and MRI pointed at active sacroiliitis. His ET was satisfactory controlled (PLT below 500 cells/mm³). Regarding all above, we decided to induce TNF-α inhibitor in therapy of AS and in august 2009 ETA was initiated subcutaneously at dose of 50mg/weekly. After four months of ETA therapy, patient was much better, his BASDAI score dropped to 2.4, C-reactive protein (CRP) was 4.9 and his liver enzymes were in normal range. Anagrelid was terminated in November 2009 and aspirin was reintroduced.
For the next six years patient was stabile, taking only ETA and aspirin.
In 
Discussion
The association of AS with IBD has already been described and subclinical gut lesions resembling CD seen in up to 50% of patients, up to 10% which developed clinically overt IBD with time (9) . Data from the IBSEN study reported the prevalence of AS in IBD to be 3.7% (2.6% in UC; 6% in CD), compared to about 1% in the general population (10).
All available TNF-α inhibitors are similarly efficacious for treatment of AS, whereas monoclonal antibodies are efficacious in the treatment of IBD and ETA is not (3). It stays unclear if development of the CD in our patient was paradoxal effect of ETA or mere occurrence of rather common extra-articular manifestation of AS, regarding the fact that ETA is not efficient in IBD. However, after ETA was discontinued from therapy and ADA introduced, successful control of both diseases was accomplished.
Although thrombocytosis in AS and IBD patients is often seen due to chronic inflammation, iron deficiency anemia or drug administration, developing of ET or other Ph-negative MPN is not common condition. We have find only four reports on the association between AS and Ph-negative MPN, three of them emerge after TNF-α inhibitor was introduced. Caramaschi et al. report a case of a 62-year old Italian with AS and bone involvement due to polycytemia rubra vera (JAK2V617 positive) (16) . Case of 69 year old men with AS and ET who was treated with ETA and hydroxyurea and developed mantle cell lymphoma (17) . Finally, a case of 34-year Korean man who developed ET following adalimumab therapy and 31-year Italian who was treated with infliximab and developed PRV, both of them shared similar genetic backgraund (HLA-B27-positive, JAK2V617-negative) (18, 19) . Our patient was diagnosed with ET years before ETA was introduced, so there is no association between occurrence of disease and TNF-α inhibitor therapy.
Today, 17 years since TNF-α inhibitors were approved for use in AS, data from real-world national registries demonstrated no increased risk of overall malignancies compared to both the general population and patients with AS without TNF-α inhibitor treatment (20) . The risk we accepted introducing TNF-α inhibitors in the treatment of ET was significant, regarding the fact that there was little data about adverse effects back in 2010. Our patient was carefully observed by hematologist, and there was any sign of ET transformation. On the contrary, ET was in remission.
According to our knowledge, there is no literature reporting association between AS, ET and CD. Although coexistence of these diseases in our patient is probably a pure coincidence, there is a possible bond. Janus kinase (JAK)/signal transducers and activators of transcription (STAT) pathway, appears to have a pivotal role in the pathogenesis of many immune-mediated diseases by facilitating the signal transduction of many different cytokines and other molecules (21) . Evidence suggests that inhibition of JAK-mediated pathways may be a promising approach for the treatment of patients with both CD and AS.
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The currently marketed drugs, tofacitinib (JAK1/3 inhibitor) and baricitinib (JAK1/2 inhibitor), show efficacy and acceptable safety in rheumatoid arthritis, UC and psoriatic arthritis, and there are encouraging results in clinical trial of tofacitinib in AS and SpA (22) . The new selective JAK1 inhibitors that are close for FDA approval for both AS and CD are upadacitinib and filgotinib (23) . On the other hand, JAK2 is crucial for signal transduction downstream of the erythropoietin, thrombopoetin, and related receptors that control erythrocyte and megakaryocyte expansion. Following the discovery of JAK2V617F in 2005 as the driver mutation of the majority of Ph-negative MPNs, quest for JAK2 inhibitor began. So far, only one JAK2/JAK1 inhibitor (ruxolitinib) was approved by the FDA in treatment of intermediate to high-risk MP and hydroxyurea-resistant or -intolerant PV. As for the ET, MAJIC trial showed the lack of superiority of ruxolitinib compared to current second-line therapies for these patients (24) .
Conclusion
In conclusion, the recent investigations and studies have improved the understanding of the pathogenesis of chronic inflammatory diseases like AS and CD, and also facilitated the development of new treatment strategies. Existence of co morbidities additionally complicate treatment of such patients. Therefore, an individual approach is essential for every physician.
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